Search results
BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer.
- PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
Poly-adenosine diphosphate ribose polymerase (PARP)...
- PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
BRCA1 and BRCA2 gene mutations account for most actionable genetic breast cancer predispositions and are increasingly used for personalised breast cancer management and PARPi therapy of BRCA-related cancer. Thus, we propose updated guidelines for BRCA testing.
3 sie 2022 · Consensus recommendations for the management of breast cancer in young women were updated from BCY4 with incorporation of new evidence to inform the guidelines. Areas of research priorities as well as specificities in different geographic and minority populations were identified.
31 maj 2023 · Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) are approved for the treatment of germline BRCA mutated (gBRCAm) breast cancer (BC) patients in the adjuvant and metastatic settings. Several studies have explored the role of PARPi in the neoadjuvant setting both with and without chemotherapy.
The guidelines will focus on cancer prevention and screening among individuals known to harbour a pathogenic BRCA1/2 mutation. The presence of a BRCA1 or BRCA2 mutation accounts for the majority of hereditary breast and ovarian cancer syndromes.
5 wrz 2022 · Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors (PARPi) are approved for BRCA1/2 carriers with HER2-negative breast cancer in the adjuvant setting with a high risk of recurrence as well as the metastatic setting.
8 kwi 2022 · PARP inhibitors have been approved for the treatment of metastatic breast cancer in germline BRCA mutation (g BRCA m) carriers. The recent OlympiA trial demonstrated improved...
